Dynamic modeling of imatinib-treated chronic myeloid leukemia: Functional insights and clinical implications

Nature Medicine

Volumn 12, Issue 10, 2006, Pages 1181-1184

  Roeder, Ingo ^a   Horn, Matthias ^a   Glauche, Ingmar ^a   Hochhaus, Andreas ^b   Mueller, Martin C ^b   Loeffler, Markus ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; DRUG EFFECT; DRUG SELECTIVITY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MATHEMATICAL MODEL; PRIORITY JOURNAL; SIMULATION;

ALGORITHMS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; COMPUTER SIMULATION; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, CHRONIC; MODELS, THEORETICAL; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION; TIME FACTORS;

EID: 33749524667     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1487     Document Type: Article

References (26)

1. Eaves, C., Udomsakdi, C., Cashman, J., Barnett, M. & Eaves, A. The biology of normal and neoplastic stem cells in CML. Leuk. Lymphoma 11 (Suppl. 1), 245-253 (1993).
2. Deininger, M.W., Goldman, J.M. & Melo, J.V. The molecular biology of chronic myeloid leukemia. Blood 96, 3343-3356 (2000).
3. Mauro, M.J. & Druker, B.J. Chronic myelogenous leukemia. Curr. Opin. Oncol. 13, 3-7 (2001).
4. Marley, S.B., Deininger, M.W., Davidson, R.J., Goldman, J.M. & Gordon, M.Y. The tyrosine kinase inhibitor STI571, like interferon-α, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia. Exp. Hematol. 28, 551-557 (2000).
5. Hehlmann, R., Hochhaus, A., Berger, U. & Reiter, A. Current trends in the management of chronic myelogenous leukemia. Ann. Hematol. 79, 345-354 (2000).
6. Cortes, J. et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin. Cancer Res. 11, 3425-3432 2005).
7. Druker, B.J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561-566 (1996).
8. Holtz, M.S. et al. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 99, 3792-3800 (2002).
9. Oetzel, C. et al. The tyrosine kinase inhibitor CGP 57148 (STI 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X. Clin. Cancer Res. 6, 1958-1968 (2000).
10. Vigneri, P. & Wang, J.Y. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat. Med. 7, 228-234 (2001).
11. Topaly, J., Fruehauf, S., Ho, A.D. & Zeller, W.J. Rationale for combination therapy of chronic myelogenous leukemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning. Br. J. Cancer 86, 1487-1493 (2002).
12. Michor, F. et al. Dynamics of chronic myeloid leukemia. Nature 435, 1267-1270 (2005).
13. Loeffler, M. & Roeder, I. Tissue stem cells: Definition, plasticity, heterogeneity, self-organization and models-A conceptual approach. Cells Tissues Organs 171, 8-26 (2002).
14. Roeder, I. & Loeffler, M. A novel dynamic model of hematopoietic stem cell organization based on the concept of within-tissue plasticity. Exp. Hematol. 30, 853-861 (2002).
15. Roeder, I. et al. Competitive clonal hematopoiesis in mouse chimeras explained by a stochastic model of stem cell organization. Blood 105, 609-616 (2005).
16. Ichimaru, M., Tomonaga, M., Amenomori, T. & Matsuo, T. Atomic bomb and leukemia. J. Radiat. Res. (Tokyo) 32 (Suppl. 2), 14-19 (1991).
17. O'Brien, S.G. et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348, 994-1004 (2003).
18. Müller, M.C. et al. Dynamics of BCR-ABL mRNA expression in first line therapy of chronic myelogenous leukemia patients with imatinib or interferon-α/ara-C. Leukemia 17, 2392-2400 (2003).
19. Jorgensen, H.G., Copland, M. & Holyoake, T.L. Granulocyte-colony- stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia. Cancer 103, 210-211 (2005).
20. Lahaye, T. et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 103, 1659-1669 (2005).
21. Hochhaus, A. & La Rosee, P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 18, 1321-1331 (2004).
22. Deininger, M.W. & Druker, B.J. SRCircumventing imatinib resistance. Cancer Cell 6, 108-110 (2004).
23. Graham, S.M. et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99, 319-325 (2002).
24. Catlin, S.N., Guttorp, P. & Abkowitz, J.L. The kinetics of clonal dominance in myeloproliferative disorders. Blood 106, 2688-2692 (2005).
25. Komarova, N.L. & Wodarz, D. Drug resistance in cancer: principles of emergence and prevention. Proc. Natl. Acad. Sci. USA 102, 9714-9719 (2005).
26. Emig, M. et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time PCR. Leukemia 13, 1825-1832 (1999).